Annual Cash & Cash Equivalents
$319.59 M
+$130.93 M+69.40%
December 31, 2024
Summary
- As of March 4, 2025, ACAD annual cash & cash equivalents is $319.59 million, with the most recent change of +$130.93 million (+69.40%) on December 31, 2024.
- During the last 3 years, ACAD annual cash & cash equivalents has risen by +$172.15 million (+116.77%).
- ACAD annual cash & cash equivalents is now -1.97% below its all-time high of $326.03 million, reached on December 31, 2020.
Performance
ACAD Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$319.59 M
+$164.44 M+105.99%
December 31, 2024
Summary
- As of March 4, 2025, ACAD quarterly cash and cash equivalents is $319.59 million, with the most recent change of +$164.44 million (+105.99%) on December 31, 2024.
- Over the past year, ACAD quarterly cash and cash equivalents has stayed the same.
- ACAD quarterly cash and cash equivalents is now -29.35% below its all-time high of $452.35 million, reached on September 30, 2020.
Performance
ACAD Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ACAD Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +69.4% | 0.0% |
| 3 y3 years | +116.8% | +116.8% |
| 5 y5 years | +68.5% | +68.5% |
ACAD Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +178.3% | at high | +225.5% |
| 5 y | 5-year | -2.0% | +178.3% | -29.4% | +237.7% |
| alltime | all time | -2.0% | +7076.0% | -29.4% | +7216.8% |
ACADIA Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $319.59 M(+69.4%) | $319.59 M(+106.0%) |
| Sep 2024 | - | $155.15 M(-12.4%) |
| Jun 2024 | - | $177.13 M(-13.5%) |
| Mar 2024 | - | $204.75 M(+8.5%) |
| Dec 2023 | $188.66 M(+64.3%) | $188.66 M(+92.1%) |
| Sep 2023 | - | $98.19 M(-9.0%) |
| Jun 2023 | - | $107.94 M(-62.9%) |
| Mar 2023 | - | $290.89 M(+153.3%) |
| Dec 2022 | $114.85 M(-22.1%) | $114.85 M(-25.8%) |
| Sep 2022 | - | $154.84 M(+10.7%) |
| Jun 2022 | - | $139.83 M(-31.8%) |
| Mar 2022 | - | $204.92 M(+39.0%) |
| Dec 2021 | $147.44 M(-54.8%) | $147.44 M(+55.8%) |
| Sep 2021 | - | $94.64 M(-64.5%) |
| Jun 2021 | - | $266.96 M(-12.3%) |
| Mar 2021 | - | $304.49 M(-6.6%) |
| Dec 2020 | $326.03 M(+71.9%) | $326.03 M(-27.9%) |
| Sep 2020 | - | $452.35 M(+45.7%) |
| Jun 2020 | - | $310.44 M(+79.4%) |
| Mar 2020 | - | $173.06 M(-8.8%) |
| Dec 2019 | $189.68 M(+40.8%) | $189.68 M(-50.8%) |
| Sep 2019 | - | $385.47 M(+417.9%) |
| Jun 2019 | - | $74.43 M(-23.7%) |
| Mar 2019 | - | $97.56 M(-27.6%) |
| Dec 2018 | $134.76 M(+94.1%) | $134.76 M(+110.9%) |
| Sep 2018 | - | $63.90 M(-13.9%) |
| Jun 2018 | - | $74.18 M(-36.2%) |
| Mar 2018 | - | $116.33 M(+67.6%) |
| Dec 2017 | $69.42 M(-57.6%) | $69.42 M(-38.4%) |
| Sep 2017 | - | $112.62 M(-21.7%) |
| Jun 2017 | - | $143.79 M(-8.6%) |
| Mar 2017 | - | $157.38 M(-3.8%) |
| Dec 2016 | $163.62 M(+60.2%) | $163.62 M(+6.5%) |
| Sep 2016 | - | $153.68 M(+16.6%) |
| Jun 2016 | - | $131.77 M(-24.8%) |
| Mar 2016 | - | $175.22 M(+71.6%) |
| Dec 2015 | $102.14 M(+65.1%) | $102.14 M(+44.3%) |
| Sep 2015 | - | $70.80 M(-24.0%) |
| Jun 2015 | - | $93.21 M(+22.0%) |
| Mar 2015 | - | $76.42 M(+23.6%) |
| Dec 2014 | $61.85 M | $61.85 M(+70.1%) |
| Sep 2014 | - | $36.37 M(+165.5%) |
| Jun 2014 | - | $13.70 M(-85.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $96.45 M(+723.9%) |
| Dec 2013 | $11.71 M(-79.8%) | $11.71 M(-0.8%) |
| Sep 2013 | - | $11.80 M(-51.3%) |
| Jun 2013 | - | $24.25 M(+31.5%) |
| Mar 2013 | - | $18.44 M(-68.2%) |
| Dec 2012 | $57.90 M(+740.5%) | $57.90 M(+622.3%) |
| Sep 2012 | - | $8.02 M(-12.9%) |
| Jun 2012 | - | $9.21 M(+65.7%) |
| Mar 2012 | - | $5.56 M(-19.3%) |
| Dec 2011 | $6.89 M(+0.6%) | $6.89 M(-17.2%) |
| Sep 2011 | - | $8.32 M(+3.7%) |
| Jun 2011 | - | $8.02 M(+17.4%) |
| Mar 2011 | - | $6.83 M(-0.3%) |
| Dec 2010 | $6.85 M(-62.2%) | $6.85 M(-29.1%) |
| Sep 2010 | - | $9.66 M(+9.6%) |
| Jun 2010 | - | $8.81 M(-51.2%) |
| Mar 2010 | - | $18.07 M(-0.3%) |
| Dec 2009 | $18.12 M(-14.4%) | $18.12 M(+4.6%) |
| Sep 2009 | - | $17.32 M(-3.7%) |
| Jun 2009 | - | $17.98 M(-4.5%) |
| Mar 2009 | - | $18.84 M(-11.0%) |
| Dec 2008 | $21.17 M(+24.6%) | $21.17 M(-4.7%) |
| Sep 2008 | - | $22.21 M(+9.5%) |
| Jun 2008 | - | $20.29 M(-3.4%) |
| Mar 2008 | - | $21.00 M(+23.7%) |
| Dec 2007 | $16.99 M(+9.7%) | $16.99 M(-27.6%) |
| Sep 2007 | - | $23.46 M(-40.8%) |
| Jun 2007 | - | $39.63 M(+77.6%) |
| Mar 2007 | - | $22.32 M(+44.2%) |
| Dec 2006 | $15.48 M(+58.0%) | $15.48 M(-41.0%) |
| Sep 2006 | - | $26.23 M(-31.7%) |
| Jun 2006 | - | $38.42 M(+241.1%) |
| Mar 2006 | - | $11.26 M(+15.0%) |
| Dec 2005 | $9.80 M(+18.0%) | $9.80 M(-58.1%) |
| Sep 2005 | - | $23.35 M(+47.7%) |
| Jun 2005 | - | $15.81 M(+40.7%) |
| Mar 2005 | - | $11.24 M(+35.3%) |
| Dec 2004 | $8.30 M(+31.6%) | $8.30 M(+45.8%) |
| Sep 2004 | - | $5.69 M(-30.2%) |
| Jun 2004 | - | $8.16 M(+86.7%) |
| Mar 2004 | - | $4.37 M(-30.8%) |
| Dec 2003 | $6.31 M(+41.6%) | $6.31 M |
| Dec 2002 | $4.45 M | - |
FAQ
- What is ACADIA Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ACADIA Pharmaceuticals?
- What is ACADIA Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is ACADIA Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ACADIA Pharmaceuticals?
- What is ACADIA Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is ACADIA Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ACAD is $319.59 M
What is the all time high annual cash & cash equivalents for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals all-time high annual cash & cash equivalents is $326.03 M
What is ACADIA Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ACAD annual cash & cash equivalents has changed by +$130.93 M (+69.40%)
What is ACADIA Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ACAD is $319.59 M
What is the all time high quarterly cash and cash equivalents for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals all-time high quarterly cash and cash equivalents is $452.35 M
What is ACADIA Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, ACAD quarterly cash and cash equivalents has changed by $0.00 (0.00%)